CNX Therapeutics acquires Sativex® global business from Jazz Pharmaceuticals

UK-based specialty pharmaceutical company CNX Therapeutics has agreed to acquire the global rights to Sativex (nabiximols) from global biopharma firm Jazz Pharmaceuticals. The deal transfers the worldwide business of the cannabinoid-based medicine, which is approved in many markets for symptoms of moderate to severe spasticity in adult patients, from Jazz to CNX.

The acquisition deepens CNX’s focus on central nervous system (CNS) therapies and strengthens its specialty medicines platform across Europe and beyond. For Jazz, the move streamlines its portfolio by handing over an established asset to a partner with a targeted commercial infrastructure. According to one report the acquisition was announced just recently.

With Sativex already licensed across multiple countries, CNX aims to leverage its agile commercial model and existing CNS-focus to maximise the brand’s reach and ensure continuity of supply for patients. Jazz will likely redirect its resources toward its core oncology and neuroscience pipeline. The deal reinforces the trend of established pharma reallocating mature assets to leaner, regionally focused players.